Ho Carole 4
4 · Denali Therapeutics Inc. · Filed Jan 8, 2025
Insider Transaction Report
Form 4
Ho Carole
Chief Medical Officer
Transactions
- Sale
Common Stock
2025-01-06$20.22/sh−12,255$247,796→ 178,580 total - Sale
Common Stock
2025-01-07$20.81/sh−2,907$60,495→ 175,673 total
Holdings
- 183,219(indirect: See footnote)
Common Stock
- 25,000(indirect: See footnote)
Common Stock
Footnotes (5)
- [F1]Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units.
- [F2]The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $19.93 to $20.23 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- [F3]Includes 134,030 Unvested RSUs.
- [F4]The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee.
- [F5]The shares are held of record by The Rohatgi-Ho Irrevocable GST Trust for the benefit of the Reporting Person's children.